BRIEF-Regenxbio Announces Additional Positive Long-Term And Interim Phase I/Iia Trial Update For Rgx-314 For The Treatment Of Wet AMD
BRIEF-Regenxbio Announces Additional Positive Long-Term And Interim Phase I/Iia Trial Update For Rgx-314 For The Treatment Of Wet AMD
April 22 (Reuters) - Regenxbio Inc RGNX.O :
* REGENXBIO ANNOUNCES ADDITIONAL POSITIVE LONG-TERM AND INTERIM PHASE I/IIA TRIAL UPDATE FOR RGX-314 FOR THE TREATMENT OF WET AMD
* REGENXBIO INC - RGX-314 CONTINUES TO BE WELL-TOLERATED AT ALL DOSE LEVELS
* REGENXBIO INC - ON TRACK TO PROVIDE ONE-YEAR DATA FROM COHORTS 4 & 5 IN MID-2020 AND INITIATE RGX-314 SUBRETINAL DELIVERY PIVOTAL PROGRAM IN 2H 2020
* REGENXBIO INC - LONG-TERM, DURABLE TREATMENT EFFECT DEMONSTRATED OVER TWO YEARS IN COHORT 3 IN WET AMD TRIAL
* REGENXBIO INC - IN WET AMD TRIAL, 50% OF PATIENTS REMAIN ANTI-VEGF INJECTION-FREE OVER TWO YEARS
* REGENXBIO INC - IN WET AMD TRIAL, 67% OF PATIENTS ARE ANTI-VEGF INJECTION-FREE FROM NINE MONTHS TO TWO YEARS
Source text for Eikon: Further company coverage:
April 22 (Reuters) - Regenxbio Inc RGNX.O :
四月二十二日(路透社)- 瑞晶生物 RGNX.O:
* REGENXBIO ANNOUNCES ADDITIONAL POSITIVE LONG-TERM AND INTERIM PHASE I/IIA TRIAL UPDATE FOR RGX-314 FOR THE TREATMENT OF WET AMD
* 瑞晶生物宣布額外的正面長期和中期階段 我/IIA 用於治療濕型 AMD 的 RGX-314 試用更新
* REGENXBIO INC - RGX-314 CONTINUES TO BE WELL-TOLERATED AT ALL DOSE LEVELS
* 麗晶生物公司-RGX-314 在所有劑量水平下仍然具有良好的耐受性
* REGENXBIO INC - ON TRACK TO PROVIDE ONE-YEAR DATA FROM COHORTS 4 & 5 IN MID-2020 AND INITIATE RGX-314 SUBRETINAL DELIVERY PIVOTAL PROGRAM IN 2H 2020
* 麗晶生物科技有限公司-將於 2020 年中期提供來自 4 和 5 群組的一年數據,並於 2020 年 2 小時啟動 RGX-314 視網膜下交付樞紐計劃
* REGENXBIO INC - LONG-TERM, DURABLE TREATMENT EFFECT DEMONSTRATED OVER TWO YEARS IN COHORT 3 IN WET AMD TRIAL
* REGENXBIO 公司-在濕式 AMD 試驗中證明了兩年以上的長期,持久的治療效果 3
* REGENXBIO INC - IN WET AMD TRIAL, 50% OF PATIENTS REMAIN ANTI-VEGF INJECTION-FREE OVER TWO YEARS
* REGENXBIO 公司-在濕式 AMD 試驗中,50% 的患者在兩年內保持抗素食注射免費
* REGENXBIO INC - IN WET AMD TRIAL, 67% OF PATIENTS ARE ANTI-VEGF INJECTION-FREE FROM NINE MONTHS TO TWO YEARS
* REGENXBIO 公司-在濕式 AMD 試驗中,67% 的患者從九個月到兩年都沒有抗素食注射
Source text for Eikon: Further company coverage:
Eikon 的來源文本:進一步的公司覆蓋範圍:
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧